Fulcrum Therapeutics, Inc.
FULCAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Jun 2, 2026 | H.C. Wainwright | Andrew Fein | $3.00(-53%) | $6.42 | TheFly |
| Jun 2, 2026 | Jefferies | $4.00(-38%) | $6.42 | StreetInsider | |
| Jun 2, 2026 | Leerink Partners | $4.00(-38%) | $6.42 | TheFly | |
| Jun 2, 2026 | Truist Financial | Gregory Renza | $4.00(-38%) | $6.42 | StreetInsider |
| Jun 2, 2026 | Piper Sandler | $3.00(-53%) | $6.42 | TheFly | |
| Feb 24, 2026 | Truist Financial | Gregory Renza | $17.00(+90%) | $8.96 | TheFly |
| Dec 11, 2025 | Truist Financial | $18.00(+42%) | $12.64 | TheFly | |
| Dec 8, 2025 | Stifel Nicolaus | $25.00(+78%) | $14.07 | TheFly | |
| Dec 8, 2025 | Cantor Fitzgerald | Kristen Kluska | $24.00(+75%) | $13.74 | TheFly |
| Dec 8, 2025 | RBC Capital | $10.00(-29%) | $14.06 | TheFly | |
| Dec 8, 2025 | Piper Sandler | $23.00(+158%) | $8.90 | TheFly | |
| Dec 8, 2025 | H.C. Wainwright | $25.00(+181%) | $8.90 | TheFly | |
| Nov 24, 2025 | Truist Financial | $14.00(+24%) | $11.29 | TheFly | |
| Nov 24, 2025 | H.C. Wainwright | Andrew Fein | $18.00(+59%) | $11.29 | StreetInsider |
| Oct 30, 2025 | Piper Sandler | $16.00(+71%) | $9.36 | TheFly | |
| Oct 21, 2025 | Leerink Partners | $20.00(+117%) | $9.22 | StreetInsider | |
| Jul 29, 2025 | H.C. Wainwright | $12.00(+58%) | $7.59 | TheFly | |
| May 29, 2025 | Piper Sandler | Edward Tenthoff | $9.00(+27%) | $7.08 | TheFly |
| May 23, 2025 | Leerink Partners | Joseph Schwartz | $12.00(+86%) | $6.44 | TheFly |
| Sep 13, 2024 | H.C. Wainwright | Andrew Fein | $4.00(+16%) | $3.44 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| JP Morgan | downgrade | Overweight →Underweight | Jun 3, 2026 |
| Stifel | downgrade | Buy →Hold | Jun 2, 2026 |
| Truist Securities | downgrade | Buy →Hold | Jun 2, 2026 |
| Piper Sandler | downgrade | Overweight →Underweight | Jun 2, 2026 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Jun 2, 2026 |
| Leerink Partners | downgrade | Outperform →Market Perform | Jun 2, 2026 |
| Truist Securities | maintain | Buy | Dec 11, 2025 |
| B of A Securities | maintain | Underperform | Dec 9, 2025 |
| HC Wainwright & Co. | maintain | Buy | Dec 8, 2025 |
| RBC Capital | maintain | Sector Perform | Dec 8, 2025 |
| Cantor Fitzgerald | maintain | Overweight | Dec 8, 2025 |
| Piper Sandler | maintain | Overweight | Dec 8, 2025 |
| HC Wainwright & Co. | maintain | Buy | Nov 24, 2025 |
| Piper Sandler | maintain | Overweight | Oct 30, 2025 |
| RBC Capital | maintain | Sector Perform | Oct 30, 2025 |
| HC Wainwright & Co. | maintain | Buy | Oct 20, 2025 |
| RBC Capital | maintain | Sector Perform | Jul 30, 2025 |
| HC Wainwright & Co. | upgrade | Neutral →Buy | Jul 29, 2025 |
| Piper Sandler | maintain | Overweight | May 29, 2025 |
| Leerink Partners | upgrade | Market Perform →Outperform | May 23, 2025 |
| Cantor Fitzgerald | upgrade | Neutral →Overweight | May 15, 2025 |
| HC Wainwright & Co. | maintain | Neutral | Feb 26, 2025 |
| RBC Capital | maintain | Sector Perform | Nov 14, 2024 |
| HC Wainwright & Co. | maintain | Neutral | Nov 14, 2024 |
| HC Wainwright & Co. | downgrade | Buy →Neutral | Sep 13, 2024 |
Earnings History
Next report: Mar 2, 2027 · EPS est. $-0.05| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Jul 30, 2026 | $-0.34 | $-0.24 | — | — |
| Apr 27, 2026 | $-0.25 | $-0.31 | — | — |
| Feb 24, 2026 | $-0.31 | $-0.31 | — | — |
| Oct 29, 2025 | $-0.31 | $-0.29 | — | — |
| Jul 29, 2025 | $-0.28 | $-0.29 | — | — |
| May 1, 2025 | $-0.28 | $-0.29 | — | — |
| Feb 25, 2025 | $-0.31 | $-0.28 | — | $142.9K |
| Nov 13, 2024 | $-0.35 | $-0.41 | — | $112.5K |
News
Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) have been assigned an average recommendation of "Reduce" from the twelve research firms that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a sell recommendation, seven have given a hold recommendation and one has issued a
Are BWIN, PTC, FULC, PRTH Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Oct. 12, 2026Insiders may stand to receive substantial financial bene
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws
New York, New York--(Newsfile Corp. - October 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - October 6, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - October 2, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - September 30, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - September 28, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Shares of Fulcrum Therapeutics, Inc. (NASDAQ: FULC - Get Free Report) have been assigned a consensus recommendation of "Reduce" from the twelve research firms that are presently covering the company, MarketBeat reports. Four investment analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and one has assigned a buy recommendation
New York, New York--(Newsfile Corp. - September 24, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
BALA CYNWYD, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
New York, New York--(Newsfile Corp. - September 22, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - September 18, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Biogen (NASDAQ: BIIB - Get Free Report) and Fulcrum Therapeutics (NASDAQ: FULC - Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability. Earnings and Valuation This table compares Biogen and Fulcrum
New York, New York--(Newsfile Corp. - September 16, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
Are ARX, FULC, EFSI Obtaining Fair Deals for their Shareholders?PR NewswireNEW YORK, Sept. 15, 2026Insiders may stand to receive substantial financial benefits
New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
New York, New York--(Newsfile Corp. - September 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.
BALA CYNWYD, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
New York, New York--(Newsfile Corp. - September 8, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Fulcrum Therapeutics, Inc. ("Fulcrum Therapeutics" or the "Company") (NASDAQ: FULC). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are a Fulcrum Therapeutics investor and have suffered losses, or if you have information that could assist in the Fulcrum Therapeutics investigation, you may CLICK HERE to contact us.